NASAL SPRAYS, AR & ASTHMA MASTERCLASS
Allergic Rhinitis, Asthma & the Role of Nasal Sprays
A field-ready guide for Bayu Healthcare Marketing Executives to understand the disease landscape and confidently communicate the value of the Nezpray brand to doctors.
What Is Allergic Rhinitis?
Allergic Rhinitis (AR) is one of the most common chronic diseases in India and worldwide. Simply put — it is an allergic inflammation of the inner lining of the nose, triggered when the immune system overreacts to harmless substances like pollen, dust mites, pet dander, or mold.
When a sensitised patient breathes in an allergen, their immune system treats it as a threat and releases a chemical called histamine. Histamine triggers the classic symptoms that patients complain about — a runny, itchy, blocked nose and sneezing.
- Rhinorrhea — constant runny nose, watery discharge
- Sneezing — often in bouts, especially in the morning
- Nasal Itch — persistent itching inside the nose
- Nasal Congestion — blocked nose, difficulty breathing
Patients may also have itchy, watery, red eyes (allergic conjunctivitis), post-nasal drip, headache, and fatigue — all of which severely impact daily functioning.
Triggered by pollen — symptoms appear during a specific season (spring, post-monsoon in India). Patients often know exactly when their "allergy season" begins.
Triggered by year-round allergens — dust mites, cockroaches, pet dander, mold. Symptoms are present throughout the year. Very common in Indian urban households.
- Intermittent — symptoms less than 4 days/week or less than 4 weeks/year
- Persistent — symptoms more than 4 days/week AND more than 4 weeks/year
- Mild — normal sleep, no impairment of daily activities, normal work/school
- Moderate / Severe — sleep disturbed, daily activities impaired, school/work affected, troublesome symptoms
Why this matters for you: Doctors use this classification to decide treatment intensity. Nezpray F is positioned from mild-to-moderate; Nezpray FA+ is the go-to for moderate-to-severe.
The Scale of the Problem
AR is massively under-treated. Most patients self-medicate with over-the-counter oral antihistamines — which are often sedating, provide partial relief, and do nothing for nasal congestion. Doctors who receive proper counselling about modern nasal sprays are far more likely to upgrade their patients to evidence-based therapy.
- Poor sleep quality — nasal blockage causes mouth-breathing and frequent waking
- Daytime fatigue, poor concentration — affects school performance and work productivity
- Anxiety and mood changes — chronic symptoms take a psychological toll
- Social limitations — patients avoid outdoor activities, parks, certain foods, pets
- Comorbidities — AR is directly linked to sinusitis, otitis media, nasal polyps, and — critically — asthma
Most patients your doctors see are undertreated. They have been using antihistamine tablets for years with incomplete relief. When you help doctors understand that a modern nasal spray like Nezpray F can offer superior, targeted, once-daily control — you are solving a real problem, not just selling a product.
Rhinitis & Asthma — One Airway, One Disease
This is arguably the most powerful clinical concept you will discuss with doctors. The nose and lungs are not separate — they are parts of a single continuous respiratory system. What happens in the nose directly affects the lungs.
Medical science now recognises this as the "United Airway Disease" concept, endorsed by the global ARIA guidelines. Here is what every Bayu executive must know and communicate:
- 80–95% of patients with asthma have allergic rhinitis — rhinitis is nearly universal in asthma
- Severe uncontrolled rhinitis is directly associated with more frequent and more severe asthma attacks
- Allergic rhinitis is an independent risk factor for developing asthma — untreated rhinitis can progress to asthma
- Treating nasal inflammation has been shown to reduce bronchial hyper-responsiveness and reduce asthma-related emergency visits
- GINA explicitly states that effective treatment of co-existing rhinitis is part of asthma management
The nasal mucosa and the bronchial mucosa share the same type of cells and the same allergic inflammatory pathway. When allergens hit the nose, the inflammatory signals travel down — through post-nasal drip, mouth-breathing of unfiltered air, and systemic cytokine release — to trigger bronchial inflammation. A blocked, inflamed nose means the lungs are working harder with less filtered, less humidified air.
"Doctor, studies show that 80–95% of your asthma patients also have rhinitis. By controlling their nasal inflammation with Nezpray F once daily, you're not just treating their nose — you're reducing the trigger burden on their lungs, which can mean fewer asthma flare-ups. And because Nezpray F has less than 0.5% systemic absorption, it adds virtually no steroid load even for patients already on inhaled corticosteroids for asthma."
Asthma is a chronic inflammatory disease of the lower airways. The airways become narrowed (bronchoconstriction), inflamed, and hypersensitive, causing wheezing, breathlessness, chest tightness, and coughing. Inhaled corticosteroids (ICS) are the backbone of asthma treatment. The key point: Nezpray F is a nasal steroid, not an asthma inhaler — but treating nasal inflammation with Nezpray F reduces the overall respiratory inflammatory burden, complementing the patient's asthma management. You are not competing with their asthma inhaler — you are completing the picture.
How Allergic Rhinitis Is Treated
Understanding the treatment options doctors have — and where intranasal steroids sit at the top — gives you the context to position Nezpray F and Nezpray FA+ with confidence.
Avoiding the trigger (dust covers, air purifiers, avoiding outdoor exposure during pollen season). Rarely sufficient on its own.
Cetirizine, loratadine, fexofenadine. Good for sneezing, itch, and runny nose. Not effective for nasal congestion. Older antihistamines cause sedation. Very widely used but frequently sub-optimal.
Gold standard, first-line treatment for moderate-to-severe AR per ARIA 2024–25 guidelines. Acts directly at the site of inflammation. Superior to oral antihistamines for all 4 nasal symptoms including congestion. This is where Nezpray F lives.
ARIA 2024–25 now conditionally recommends INAH+INCS combinations when INCS alone is insufficient. Fixed-dose combination like Nezpray FA+ is the modern evidence-based step-up option — dual mechanism, one bottle.
| Feature | Intranasal Steroids (Nezpray F) | Oral Antihistamines |
|---|---|---|
| All 4 Nasal Symptoms | ✓ All four including congestion | ✗ Poor for congestion |
| Ocular Symptoms | ✓ Documented (with fluticasone furoate) | Partial |
| Site of Action | Direct — nasal mucosa | Systemic — whole body |
| Sedation | None | Common with older types |
| Systemic Side Effects | Minimal (<0.5% bioavailability for FF) | Yes — CNS, cardiac |
| ARIA Guideline Rank | First-line for moderate-severe AR | First-line for mild AR only |
Sometimes used as add-on therapy, particularly in patients with both AR and asthma. However, ARIA guidelines position them below intranasal steroids. Not a front-line choice for AR alone. Doctors may ask about this — you can say Nezpray F is ranked ahead of LTRAs for AR as per current guidelines.
NEZPRAY F — Everything You Need to Know
NEZPRAY F™
Fluticasone Furoate Nasal Spray · 27.5 mcg per spray · 12 mL · 120 Doses · Once Daily
- What it contains: Fluticasone Furoate (FF) — a 3rd-generation enhanced-affinity intranasal corticosteroid. The most advanced INCS available.
- How it works: FF binds to glucocorticoid receptors in the nasal lining with the highest affinity of any INCS (RBA 2989). It switches off the inflammatory genes that cause all 4 nasal symptoms — and uniquely, also reduces ocular (eye) symptoms.
- How long to take: Regular daily use for sustained control. Effects begin in 8 hours; full benefit in 1–2 weeks of regular use.
- Who takes it: Adults and adolescents ≥12 yrs (2 sprays/nostril OD); Children 2–11 yrs (1 spray/nostril OD)
- Highest Receptor Affinity (RBA 2989): Among all intranasal corticosteroids on the market, FF binds most powerfully to the anti-inflammatory receptor. Think of it as the tightest lock-and-key fit — more potency, less molecule needed.
- Fastest Onset Among INCS — 8 Hours: Most intranasal steroids take 24–48 hours to show any effect. FF shows measurable improvement within 8 hours of the very first dose. Patients feel it working sooner — and this matters for adherence.
- Least Systemic Absorption (<0.5%): Almost nothing enters the bloodstream. This is why Nezpray F is uniquely safe for children from age 2, the elderly, and patients already on inhaled steroids for asthma. No cortisol suppression observed in any clinical trial.
- Covers Eye Symptoms Too: This is a unique differentiator vs. other INCS. Fluticasone furoate has documented evidence of relieving itchy, watery, red eyes — eliminating the need for additional eye drops for most patients. Doctors love this.
- Longest Receptor Residence Time (10.5 hours): FF stays bound to the receptor for longer than any competitor (FP = 7.8 hrs; budesonide = 5 hrs). This means genuine once-daily dosing with all-day protection — a real convenience advantage over twice-daily alternatives.
- No HPA axis (cortisol) suppression at approved doses in any clinical trial
- No mucosal atrophy observed on nasal biopsies even after long-term use
- No evidence of growth inhibition in children at approved doses
- No increased risk of cataracts or glaucoma (unlike systemic steroids)
- Most common side effect: mild epistaxis (nosebleed) in 4–8% — expected with any nasal spray; not a safety concern
- Adult or child with seasonal or perennial AR needing first-line treatment
- Patients with significant eye symptoms alongside nasal symptoms
- Patients on multiple medications who need simplification (once-daily only)
- Asthmatic patients on inhaled corticosteroids — Nezpray F adds minimal systemic steroid load
- Children aged 2–11 — approved, safe, effective
- Patients switching from oral antihistamines who still have congestion or eye symptoms
NEZPRAY FA+ — Everything You Need to Know
NEZPRAY FA+™
Azelastine HCl + Fluticasone Propionate Nasal Spray · 7 gm · 70 Doses · Twice Daily · Age ≥12 years
- What it contains: Two active ingredients — Azelastine (an intranasal antihistamine) + Fluticasone Propionate (a corticosteroid) — in one fixed-dose spray.
- How it works: Azelastine blocks histamine within 15 minutes (early-phase); Fluticasone propionate suppresses the deeper inflammatory cascade over hours (late-phase). Together, they cover the full 24-hour allergic response cycle that neither can alone.
- Who takes it: Adults and adolescents ≥12 years with moderate-to-severe AR, especially those whose symptoms are not fully controlled on INCS alone.
- Dosing: 1 spray per nostril, twice daily (morning + evening)
When a patient is exposed to an allergen (say, dust or pollen), the allergic response happens in two waves:
Mast cells release histamine immediately → instant sneezing, itch, runny nose. Azelastine blocks this in 15 minutes by occupying the H1 receptor on nasal cells before histamine can bind.
Inflammatory cells (eosinophils, T-cells) infiltrate the nasal lining → persistent congestion, swelling, hyper-reactivity. Fluticasone propionate suppresses this cascade.
Result: Complete dual-phase coverage — the rapid antihistamine relief patients want, combined with the sustained steroid control that actually resolves the underlying inflammation.
Unlike oral antihistamines, azelastine is more than just an H1 blocker. It also:
- Stabilises mast cells (reduces histamine release at source)
- Inhibits other inflammatory mediators — LTC4, PAF, substance P, bradykinin, IL-6, TNF-α
- Effectively relieves nasal congestion — oral antihistamines generally cannot do this
- Works in 15 minutes — unlike INCS which take hours to days for initial effect
A published systematic review of 8 randomised controlled trials (PRISMA-compliant, peer-reviewed) confirmed:
- AzeFlu combination vs. azelastine alone: TNSS improvement of −1.40 (p < 0.001) — statistically significantly better
- AzeFlu combination vs. fluticasone alone: TNSS improvement of −0.74 (p < 0.001) — statistically significantly better
- All 8 studies showed greater symptom reduction with the combination vs. either monotherapy
TNSS = Total Nasal Symptom Score — the standard validated measure doctors use to assess AR severity.
- Patient with moderate-to-severe AR — especially where congestion + sneezing + itch are all prominent
- Patient who was on Nezpray F (or another INCS) but still has breakthrough symptoms
- Patient using a separate nasal antihistamine + a separate steroid spray — consolidate into one bottle
- Patient with prominent early-morning nasal symptoms (azelastine's 15-min onset is ideal)
- Asthmatic patient with uncontrolled rhinitis — comprehensive nasal control reduces trigger load on lungs
Which Product, When?
Being able to clearly articulate which product fits which patient builds instant credibility with doctors. Here is a simple, memorable framework.
NEZPRAY F
The First Choice
Best for:
- ✦ Mild-to-moderate AR — first-line INCS
- ✦ Children (2–11 years)
- ✦ Eye symptoms alongside nasal symptoms
- ✦ Patients on asthma inhalers (ultra-safe)
- ✦ Patients switching from oral antihistamines
- ✦ Pre-season prophylaxis (start 2–4 weeks early)
NEZPRAY FA+
The Step-Up
Best for:
- ✦ Moderate-to-severe AR
- ✦ Inadequate control on INCS alone
- ✦ Dominant sneezing + itch phenotype
- ✦ Early-morning nasal breakthrough
- ✦ Asthma + severe uncontrolled rhinitis
- ✦ Patients on 2 separate nasal sprays (simplify)
Start with Nezpray F. If the patient comes back and their nose is still running, still blocked, still sneezing — step up to Nezpray FA+. This mirrors the ARIA 2024–25 guideline recommendation exactly.
Talking to Doctors — Scripts That Work
The following are ready-to-use conversational openers and talking points tailored to different doctor types. Adapt naturally — don't read them verbatim.
Opener "Doctor, how many patients come to you each week with a runny or blocked nose that won't go away? Many of them have probably been on cetirizine for months with incomplete relief, especially for the blocked nose — because antihistamines don't work well for congestion."
Key Message "Nezpray F — fluticasone furoate — gives you once-daily coverage of all four nasal symptoms including congestion, with onset in just 8 hours. It's also the only INCS proven to relieve eye symptoms. And because it has less than 0.5% systemic absorption, it's approved all the way down to 2 years of age."
Close "For your next patient who comes in with year-round rhinitis and isn't satisfied with their antihistamine, Nezpray F once daily could be the upgrade that actually changes their quality of life."
Opener "Doctor, for your patients with moderate-to-severe persistent AR who still have breakthrough symptoms despite being on a nasal steroid — have you tried the fixed-dose azelastine-fluticasone combination?"
Key Message "Nezpray FA+ gives you dual-phase blockade — azelastine for the immediate histamine response in 15 minutes, and fluticasone propionate for the sustained late-phase inflammation. A meta-analysis of 8 RCTs showed the combination is statistically superior to either drug alone. ARIA 2024–25 now conditionally recommends this class of combination over INCS monotherapy."
Close "For your toughest AR patients — the ones you see every few months still complaining — Nezpray FA+ is a one-bottle upgrade with evidence behind it."
Opener "Doctor, what percentage of your asthma patients do you think also have rhinitis? Studies show it's 80 to 95%. Uncontrolled rhinitis actually worsens asthma control — it increases bronchial hyper-responsiveness and leads to more exacerbations."
Key Message "Nezpray F — fluticasone furoate nasal spray — has less than 0.5% systemic absorption, so it adds virtually no steroid load even for patients already on budesonide or fluticasone propionate inhaler. Treating their nasal inflammation with Nezpray F protects the lower airway — fewer asthma triggers reaching the lungs, better overall respiratory control."
For Severe Cases "For asthmatic patients with truly uncontrolled rhinitis, Nezpray FA+ gives rapid dual-mechanism nasal control. The azelastine component works in 15 minutes — immediate morning relief when many asthmatic patients have their worst symptoms."
Opener "Doctor, for children with persistent rhinitis — especially the ones who snore, mouth-breathe, or have recurrent ear infections — an effective nasal steroid can make a remarkable difference. The challenge is finding one with an established paediatric safety record."
Key Message "Nezpray F — fluticasone furoate — is approved from age 2 years. With less than 0.5% systemic bioavailability, there are no HPA axis concerns and no growth effects have been observed at approved doses in clinical trials. Once daily, side-actuated device — easy for parents to administer."
Tough Questions Doctors Ask
These are the most common objections you will face in the field. Know these answers confidently — a calm, evidence-based response builds trust far more than avoiding the question.
The Cheat Sheet — Carry This in Your Head
| What Doctor Says | Your Response Direction | Product |
|---|---|---|
| "My patient's nose is constantly runny and blocked" | INCS superior to antihistamines for all symptoms including congestion | Nezpray F |
| "Child 5 years old with persistent rhinitis" | Approved from age 2; <0.5% bioavailability; no growth concerns | Nezpray F |
| "Patient on budesonide inhaler for asthma" | Nezpray F adds virtually no systemic steroid load; treats the United Airway | Nezpray F |
| "Patient still sneezing despite nasal steroid" | Step up to INCS+INAH — ARIA 2024–25 supports; meta-analysis proven superior | Nezpray FA+ |
| "Severe rhinitis, congestion, sneezing, watery eyes all together" | Dual mechanism — early AND late phase; one bottle covers everything | Nezpray FA+ |
| "My asthmatic patient's nose is also always blocked" | Uncontrolled rhinitis worsens asthma; FA+ for comprehensive nasal control | Nezpray FA+ |
| "Patient using two separate nasal sprays" | Simplify to one bottle; proven superior to sequential administration | Nezpray FA+ |
Nezpray F: "The most advanced once-daily nasal steroid — highest receptor affinity, fastest onset, safest systemic profile, and the only INCS that also relieves eye symptoms."
Nezpray FA+: "When a single spray isn't enough — the dual-mechanism, guideline-supported step-up that combines 15-minute antihistamine relief with sustained steroid control in one bottle."
Every doctor you meet is treating patients who are suffering unnecessarily — patients who have been on cetirizine tablets for years, who can't sleep properly, who miss work, who have asthma attacks they didn't know were triggered by their nose. You have two products that can genuinely change that story. Know the disease, know the science, know the patient — and you will never feel like you're just "selling." You will feel like you're solving a problem. That is what builds lasting relationships with doctors, and what builds the Nezpray brand.